Result for
Tag: variants
May 27, 2021
Standardised Quantitative Neutralisation Responses to SARS-CoV-2 Variants of Concern by Convalescent Anti-Sera from First Wave Infections of UK Health Care Workers and Patients
[Pre-print, not peer-reviewed] Neutralizing activity of convalescent plasma collected from patients and healthcare workers infected during the first wave of the COVID-19 pandemic between July and September 2020 (n=61) was reduced by 2-fold against the B.1.1.7 variant and by 8-fold against the B.1.351 and P.1 variant compared to the parent B.1 strain. Neutralizing activity correlated…
Emergence of a New SARS-CoV-2 Variant from GR Clade with a Novel S Glycoprotein Mutation V1230L in West Bengal India
[Pre-print, not peer-reviewed] Genomic surveillance detected a potential new variant emerging in West Bengal, India from an analysis of over 2,000 sequenced samples collected from January to March 2021. The new variant, identified in 70 of 412 sequences submitted from West Bengal, is characterized by 11 mutations including V1230L and P681H, also found in the…
May 25, 2021
Effectiveness of COVID-19 Vaccines against the B.1.617.2 Variant
[Pre-print, not peer-reviewed] Effectiveness of the Pfizer-BioNTech vaccine against symptomatic SARS-CoV-2 infection following 1 dose was 34% against the B.1.617.2 variant of concern (first described in India) compared to 51% against the B.1.1.7 variant in a case control analysis of 12,675 sequenced cases in England (92% B.1.1.7). Two-dose effectiveness was modestly lower, with 88% against…
May 21, 2021
Infection and Vaccine-Induced Neutralizing Antibody Responses to the SARS-CoV-2 B.1.617.1 Variant
[Pre-print, not peer-reviewed] An in-vitro study of neutralizing antibody response to the B.617.1 variant found that the variant was 6.8-fold more resistant to neutralization by sera from persons previously infected with SARS-CoV-2 (N=24) and individuals vaccinated with either the Pfizer-BioNTech (N=10) or Moderna (N=15) vaccines compared to a wild type strain. However, 79% of serum…
Mutation-Specific SARS-CoV-2 PCR Screen: Rapid and Accurate Detection of Variants of Concern and the Identification of a Newly Emerging Variant with Spike L452R Mutation
An evaluation of a novel multiplex, mutation-specific PCR-based assay on 247 SARS-CoV-2 positive samples found 100% concordance for strain typing of variants B.1.1.7 and P.1 compared to whole genome sequencing methods. This method detects five variants of concern and three variants of interest, including the B.1.526.1 variant emerging in the Eastern US. The assay can…
Emergence and Spread of the Potential Variant of Interest (VOI) B.1.1.519 Predominantly Present in Mexico
[Pre-print, not peer-reviewed] Investigators described the emergence and spread of a novel SARS-CoV-2 variant of interest (B.1.1.519) in Mexico with mutations T478L, P681H, and T732A in the spike protein. Out of 2,692 SARS-CoV-2 samples analyzed for genomic sequence between March 1, 2020 and March 21, 2021, 37.8% were B.1.1.519. The variant was not detected prior…
May 19, 2021
Rapidly Emerging SARS-CoV-2 B.1.1.7 Sub-Lineage in the United States of America with Spike Protein D178H and Membrane Protein V70L Mutations
[Pre-print, not peer-reviewed] Genomic surveillance of SARS-CoV-2 cases identified an expanding US-specific sub-lineage of the B.1.1.7 variant. This sub-lineage is characterized with sequential acquisition of a membrane protein mutation, V20L, in November 2020 and a spike mutation, D178H, in early February 2021. The proportion of B.1.1.7 isolates in the US belonging to this sub-lineage increased…
May 18, 2021
Serial Interval of COVID-19 and the Effect of Variant B.1.1.7 Analyses from a Prospective Community Cohort Study (Virus Watch)
[Pre-print, not peer-reviewed] The mean interval between exposure to COVID-19 and the development of symptoms was 3.2 days, according to an analysis of 186 likely infector-infectee pairs in England and Wales. The mean serial interval in individuals belonging to households in regions and belonging to study weeks classified as having a high percentage of infections…
May 17, 2021
The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-Elicited and Therapeutic Monoclonal Antibodies
[Pre-print, not peer-reviewed] The SARS-CoV-2 B.1.617 and B.1.618 strains currently circulating in India were found to have specific spike protein mutations (B.1.617 = L452R/E484Q/D614G/P681R, B.1.618 = Δ145-146/E484K/D614G) that were somewhat resistant to neutralization by sera from convalescent individuals, vaccine-elicited antibodies, and therapeutic monoclonal antibodies; but not enough to suggest that current vaccines will not be…
Durability of MRNA-1273-Induced Antibodies against SARS-CoV-2 Variants
[Pre-print, not peer-reviewed] An analysis of sera from participants in the Moderna vaccine trial (n=24) found that most individuals maintained both binding and functional antibodies against the B.1.1.7, B.1.351, P.1, B.1.429, and B.1.526 SARs-CoV-2 variants for 6 months, although at lower levels relative to wildtype and D614G. The B.1.1.7 lineage had little impact on antibody…
Previous page Next page